Artelo biosciences announces presentation of phase 1 data with art27.13 in cancer-related anorexia

Phase 1 data from the cares trial showed an attractive safety profile and promising activity from daily art27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment phase 1 data from the cares trial showed an attractive safety profile and promising activity from daily art27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment
ARTL Ratings Summary
ARTL Quant Ranking